hTERT + Survivin combination therapy

hTERT + Survivin is a combination immunotherapy approach that targets two critical tumor-associated antigens: human telomerase reverse transcriptase (hTERT) and survivin (BIRC5). Both proteins are highly expressed in most cancers and play crucial roles in cancer cell survival and proliferation[1][2]. This therapeutic approach has been implemented in several ways: - As a multipeptide vaccine containing both hTERT and survivin peptides - In combination with adoptive T-cell transfer following autologous stem cell transplantation - As dendritic cell (DC) vaccination loaded with hTERT and survivin mRNA The therapy works by inducing immune responses against these tumor-associated antigens, potentially leading to enhanced anti-tumor immunity. Clinical trials have shown that this combination can induce immune responses in approximately 36% of patients, which exceeds the response rates seen with other cancer vaccines like idiotype vaccines after autotransplantation[1].

Other names

hTERT/survivin multipeptide vaccinationhTERT and survivin targeting